SS
XFOR icon

Steve Schonfeld’s X4 Pharmaceuticals XFOR Stock Holding History

Steve Schonfeld’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,514
Closed -$80.6K – 3059
2026
Q1 		$80.6K Buy
+19,514
New +$73.1K ﹤0.01% 1916
2025
Q3 		– Sell
-11,261
Closed -$21.4K – 2632
2025
Q2 		$21.4K Buy
11,261
+80
+0.7% +$327 ﹤0.01% 1931
2025
Q1 		$79.3K Sell
11,181
-35,247
-76% -$485K ﹤0.01% 2040
2024
Q4 		$1.02M Sell
46,428
-17,599
-27% -$281K 0.01% 1102
2024
Q3 		$1.29M Buy
64,027
+21,704
+51% +$453K 0.01% 1072
2024
Q2 		$736K Buy
42,323
+11,823
+39% +$387K ﹤0.01% 1336
2024
Q1 		$1.27M Buy
30,500
+12,190
+67% +$339K 0.01% 1139
2023
Q4 		$461K Sell
18,310
-1,225
-6% -$29.8K ﹤0.01% 1313
2023
Q3 		$639K Sell
19,535
-13,255
-40% -$578K 0.01% 1146
2023
Q2 		$1.91M Sell
32,790
-1,777
-5% -$91.3K 0.02% 766
2023
Q1 		$902K Buy
34,567
+4,724
+16% +$139K 0.01% 995
2022
Q4 		$889K Buy
+29,843
New +$1.41M 0.01% 1210

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Steve Schonfeld's XFOR Position: Q2 2026 in Review

Steve Schonfeld sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 19,514 shares — an estimated $80.6K sold.

Steve Schonfeld first reported a position in XFOR in Q4 2022 and held it in 12 quarters. The position peaked at $1.91M in Q2 2023. 88 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Steve Schonfeld reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 19,514 X4 Pharmaceuticals shares in Q2 2026, an estimated $80.6K.
  • Steve Schonfeld first reported a position in X4 Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Steve Schonfeld's X4 Pharmaceuticals position peaked at $1.91M in Q2 2023.
  • 88 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.